DHA Brain Delivery Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

365 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-09-01

Study Completion Date

2024-05-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Carrying the APOE ɛ4 allele is the strongest genetic risk factor for developing Alzheimer's disease. The goal of this project is to identify whether carrying the APOE ɛ4 allele is associated with reduced delivery of DHA to the brain. This information will help us identify the target population that could benefit from DHA supplementation to prevent cognitive decline.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

NCT06304883

Early Alzheimer's Disease

ACTIVE_NOT_RECRUITING PHASE3

Memory Impairment Study (Mild Cognitive Impairment Study)

NCT00000173

Alzheimer Disease

COMPLETED PHASE3

An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

NCT04770220

Early Alzheimer's Disease

COMPLETED PHASE3

Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease

NCT04693520

Early Alzheimer's Disease

COMPLETED PHASE2

A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

NCT04971733

Alzheimer Disease

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Brain DHA Delivery Trial will examine the effect of APOE genotype on the changes of cerebrospinal fluid (CSF) DHA to Arachidonic acid (AA) ratio in 184 cognitively healthy older individuals in response to DHA supplementation. Randomized clinical trials have yielded mixed results on the effect DHA supplementation on cognitive outcomes. This study asks the critical question of whether DHA gets into the brain in sufficient amounts after supplementation, and whether APOE genotype affects brain penetrance.

This trial will also test the effect of DHA supplementation on changes in brain structural and functional connectivity assessed by MRI, and changes in cognition after two years of supplementation in all 368 participants.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Brain DHA Delivery and Alzheimer's Disease Risk

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

double blind and randomized placebo controlled

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DHA

oral DHA supplementation at 2 grams per day

Group Type EXPERIMENTAL

DHA

Intervention Type DRUG

DHA supplementation

Placebo

Placebo for DHA

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo for DHA

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DHA

DHA supplementation

Intervention Type DRUG

Placebo

Placebo for DHA

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: ≥ 55 and ≤ 80
* At least one dementia risk factor (obesity, education years, hypertension, hyperlipidemia)
* Mini-Mental State Examination (MMSE) ≥ 25
* Logical Memory II delayed recall score ≥ 6 and ≤ 18 .

Exclusion Criteria

* Diagnosis of dementia as assessed by the investigator
* Use of omega-3 preparations in the last 3 months
* \> 200 mg/day of DHA consumption using a validated questionnaire
* Use of donepezil, rivastigmine, galantamine and/or memantine
* Alcohol or drug abuse
* A concomitant serious disease such as active cancer treatment or HIV.
* Participation in a clinical trial in the last 30 days
* Use of anticoagulants such as Plavix or Coumadin or the newer generation blood thinners.

Minimum Eligible Age

55 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes